97 results
8-K
EX-99.1
ALLK
Allakos Inc
14 Mar 24
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:15pm
related to Allakos’ ability to realize the contemplated benefits of its restructuring and related reduction in force; Allakos’ ability to accurately
8-K
EX-99.1
ALLK
Allakos Inc
26 Feb 24
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
7:05am
additional product
candidates beyond AK006; uncertainties related to Allakos’ ability to realize the contemplated benefits of its restructuring
8-K
EX-99.1
ALLK
Allakos Inc
12 Feb 24
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
7:07am
beyond AK006; uncertainties related to Allakos’ ability to realize the contemplated benefits of its restructuring and related reduction in force
8-K
EX-99.1
3nw8mo gityl093j
16 Jan 24
Regulation FD Disclosure
6:17pm
8-K
EX-99.1
4zpf1k h1q1xeb6vl
16 Jan 24
Allakos Announces a Restructuring to Focus on Development of AK006
5:00pm
424B5
e52 qx1i2i6qf
19 Sep 22
Prospectus supplement for primary offering
7:32am
8-K
EX-99.2
8quk2 srjrnl9e5b
19 Sep 22
Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock
7:14am
8-K
EX-1.1
a0tn5wvpqssh
19 Sep 22
Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock
7:14am
8-K
EX-1.1
vk9e0vvrnk9a09c
4 Aug 22
Entry into a Material Definitive Agreement
5:31pm
424B5
2vg2zn
4 Aug 22
Prospectus supplement for primary offering
5:30pm
8-K
EX-99.1
mkrexeqb
21 Jun 22
Other Events
5:08pm